Ocular allergy therapy perspectives: Review on the main therapeutic targets

Perspectivas no tratamento da alergia ocular: Revisão das principais estratégias terapêuticas

Leda das Neves Almeida Sandrin¹, Ruth Miyuki Santo²

ABSTRACT

Ocular allergies encompass a number of inflammatory diseases in the ocular surface which have different hypersensitivity mechanisms and occur in 20% of population. They can be classified as being type I hypersensitivity mediated (PAC, SAC), type I and IV (VKC, AKC) and type IV (BKC, GPC). The most prevalent forms are PAC and SAC. The chronic presentations are mostly related to visual impairment due to remodeling in the ocular surface caused by chronic inflammation. Dry eye disease and keratoconus are comorbidities observed in severe cases. The management is based on accurate diagnosis, avoidance of etiological factors and the rational use of drugs that control the inflammatory events caused by Th2 driven. The advances in knowledge on activation and traffic of immune cells are providing new drugs and many perspectives on different approaches.

Keywords: Conjunctivitis, allergic/physiopathology; Conjunctivitis, allergic/drug therapy; keratoconjunctivitis; Drug hypersensitivity; Hypersensitivity, immediate; Immunoglobulin E

RESUMO

As alergias oculares englobam uma série de doenças inflamatórias da superfície ocular, causadas por diferentes mecanismos de hipersensibilidade. Acometem aproximadamente 20% da população e podem ser classificadas em formas mediadas por hipersensibilidade tipo I (CAS, CAP), tipo I e IV (CCV, CCA) e tipo IV (BCC, CPG). As formas mais prevalentes são CAS e CAP. As formas crônicas (CCV, CCA), estão mais frequentemente relacionadas a complicações e comprometimento da função visual decorrentes do processo inflamatório e consequente remodelação da superfície ocular. Comorbidades como olho seco e ceratocone podem estar presentes. O tratamento envolve diagnóstico e afastamento dos fatores etiológicos envolvidos, uso de drogas antiinflamatórias que atuem na ação de linfócitos Th2, eosinófilos, mastócitos e células dendríticas. Avanços no conhecimento da ativação e tráfego de células do sistema imune têm sido promissores na perspectiva de novas abordagens terapêuticas.

Descritores: Conjuntivite alérgica/fisiopatologia; Conjuntivite alérgica/quimioterapia; Keratoconjuntivite; Hipersensibilidade a drogas; Hipersensibilidade imediata; Imunoglobulina E
CLINICAL PROFILE OF EYE ALLERGY

Eye allergy refers to a heterogeneous group of allergic diseases of the eye surface whose cardinal symptom is pruritus. Epidemiological studies on the prevalence and incidence of eye allergy are conflicting due to the difficulties in standardization of nomenclature and diagnosis(1), as well as due to the questionnaires prioritize the term allergic rhinoconjunctivitis and in most cases do not use specific questions about eye allergy isolatedly(2). In general, a high prevalence (20%) observed. Although responsible for the decrease in quality of life in a significant number of patients both by the hassle of symptoms or the complications of it, it is still an underdiagnosed disease, and self-medication is frequent(4). Studies show that few patients are evaluated by expert ophthalmologists and/or allergists(5). However, severe cases (2%) generally go to specialized services, which may be responsible for their high prevalence in some studies(8).

Mild forms account for about 98% of cases(5), and are characterized by two syndromes: A perennial allergic conjunctivitis (PAC) and seasonal allergic conjunctivitis (SAC), often associated to other systemic allergic diseases such as allergic rhinitis, asthma and atopic dermatitis. The perennial form is associated to environmental allergens such as mites, cockroaches, animal epithelia and fungi. The seasonal form occurs predominantly in southwestern Brazil from August to December, and relates to the exposure and sensitization to airborne vegetable allergens, especially grass pollen(5-6). The main symptoms are itchy eyes, conjunctival hyperemia, tearing and conjunctival edema and/or chemosis, and corneal ulcerations may rarely occur due to the continuous itching. The seasonal form tends to be more intense due to the unavoidable exposure to aeroallergens, and PAC patients may present chronic conditions getting seasonally worse due to the polysensitization.

Chronic and severe forms, although rare, can be devastating. They are divided into two groups: vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC). In such cases, inflammation mediated by type I hypersensitivity with IgE production may or may not be present, although the inflammatory effect arising from the infiltration and activation of eosinophils and lymphocytes resulting from type IV hypersensitivity always occur.

Atopic keratoconjunctivitis (AKC) usually affects adult patients from the third and fourth decades and patients with atopic dermatitis since childhood. Advanced cases of AKC occur with sub-epithelial fibrosis, symblepharon, buds, corneal ulceration, neovascularization, decreased goblet cells and occasionally cataracts. The main symptoms include intense itching, photophobia, burning sensation and foreign body. The main findings in clinical examination are buds on the upper and lower tarsus, injection and conjunctival edema, atopic dermatitis on the eyelids, puncta cornal erosions and shield ulcer.

VKC takes place in the first and second decades of life, and is prevalent in boys (3/1) and usually disappears in adulthood(7). It may be with or without atopy. It has two main forms, the limbic one with Horner Trantas nodules and limb edema, and the tarsal form with tarsal buds, and both forms may coexist. The main symptoms are itching, photophobia, mucous secretion, conjunctival hyperemia and pain associated to corneal lesions.

The BCC is an inflammatory process caused by type IV hypersensitivity, secondary to the contact dermatitis caused by haptnens applied to the conjunctiva and/or eyelid. BCC may coexist associated to other forms of conjunctivitis and even be caused by hypersensitivity due to allergy to the active ingredients and preservatives present in eyedrops.

PATHOPHYSIOLOGY

The pathophysiology of eye allergy is associated to the inflammatory response generated by types I and IV hypersensitivity mechanisms characteristic of the activation actions of the subtype of Th2 lymphocytes, mast cells and eosinophils(6-10). Some studies have shown the activation of lymphocyte subsets Th1 in CCA(8). Thus, genetically predisposed patients and exposed to various environmental allergens can initiate the allergic response by the antigen processing performed by non-lymphoid dendritic cells (DC) present in eye surface. Once the antigen (allergen) is processed, the dendritic cell is activated and initiates the release of inflammatory interleukins as the factor of tumor necrosis , IL-1 and IL-6 as well as increased surface protein expression (CCR7, MHC-II ), important for the migration to peripheral lymph organs and antigen presentation to Th0 lymphocytes via MHC II (major histocompatibility complex)(9).

After antigen recognition, Th0 lymphocytes change into Th2 cells producing IL-4, IL-5 and IL-13, which are the interleukins responsible for the activation and transformation of B lymphocytes into plasma cells producing IgE. Once produced, the specific IgE circulates and binds to high affinity receptors present on the membrane of the mast cells of the eye surface, making them sensitized(10).

During the antigen rechallenge, the sensitized mast cells degranulate by destabilization of the membrane caused by the crosslinking of IgE, releasing pre-formed mediators such as histamine and tryptase clinically causing the symptoms of itching, edema, and hyperemia after binding to the histamine receptors. This is a response which occurs rapidly after the exposure to the allergen, and lasts about 30 minutes. After the release of preformed granules, the arachidonic acid metabolism activation via phospholipase A2 in the membrane of mast cells leads to the production of prostaglandins and leukotrienes, responsible for the late response, 4 to 6 hours after the initial response, with reappearance of inflammatory symptoms and infiltration of neutrophils and eosinophils(11).

It is important to remember that currently four types of histamine receptors (H1, H2, H3 and H4) are known and distributed in different cells and with different biological functions(11). Special attention must be given to the H4 receptors responsible for the activation / modulation of the innate immune system cells such as epithelial cells, NK cells, antigen presenting cells and eosinophils(4).

Interleukins IL-4, IL-5, IL-6, IL-8, IL-13 produced by Th2 lymphocytes and activated TC mast cells present on the eye surface favor the maturation, migration, and activation of eosinophils(12-13). The eosinophilic inflammation causes tissue damage through a variety of proteins released as cationic protein, most basic protein, peroxidase and neurotoxin, and is responsible for the remodeling of the eye surface and maintenance of the symptoms in chronic conjunctivitis(12-14). Interleukins associated to Th1 stimulus (factor of tumor necrosis and interferon gamma)
as proposed to the pathophysiology of AKC, may be associated to a decreased function of the goblet cells and consequent changes in the eye surface and the dry eye syndrome observed in these patients. Severe forms of allergy (AKC, VKC) may present inflammation mediated by lymphocytes, neutrophils and eosinophils without increasing serum IgE or eye surface, characterizing a hypersensitivity inflammation of type IV(15).

The immune process described above can be presented with varying intensities due to environmental and genetic factors involved in the production of different subtypes of cytokines responsible for maintaining the inflammatory activity. The determination of cytokine levels in tears and the genetic analysis of protein expression in the eye surface cells of the eyes affected by allergic conjunctivitis show the phenotypic difference in different clinical presentations(16-17).

**Assorted complications**

Keratoconus and dry eye are complications that may be associated to or be made worse by inflammation of the eye surface and the continuous itching, which is key in the early diagnosis and guidance in these cases(18). The frequent association between keratoconus with atopy and chronic ocular itching has been described(19), and early development of keratoconus in patients with VKC has been observed(20). Frequent use of electronic devices associated to the high number of allergic conjunctivitis cases may be related to the high prevalence of dry eye syndrome found in the studies(21-22).

**Treatment**

The main goals of the treatment are reducing the symptoms and minimizing the complications by controlling the inflammatory process through preventive, pharmacological and environmental measures. It should be noted that allergic diseases of the eye surface need to be addressed by a multidisciplinary team(23) mainly involving ophthalmologists and allergists, and ocular and systemic comorbidities must be promptly diagnosed and treated.

Mild allergic conjunctivitis are the most frequent ones and generally mediated by IgE, and therefore their treatment depends on the etiologic diagnosis that can be accomplished by skin tests with immediate response by blocking the H1 receptors as well as the delayed response by stabilizing the membrane of mast cells with subsequent inhibition of activation and chemotaxis of eosinophils. Among the main drugs of this group are ketotifen, epinastine, and olopatadine(24) and alcaftadine. Small variability in the mechanism and time of action between these drugs has been described. Comparative studies in animal and humans models between olopatadine and alcaftadine show a more prolonged effect on the control of itching, and a decreased recruitment of eosinophils using the alcaftadine 0.25%, probably related to its action on H4 receptor(27-28). They are relatively safe drugs, but may cause adverse effects resulting from the action on muscarinic and alpha adrenergic receptors, and should be used with caution in patients with narrow angle. Suitable for all types of allergic conjunctivitis, they are well tolerated, and presentations of daily use only favor adhesion to the treatment(25-28).

**Corticosteroids**

The use of topical corticosteroids is quite effective in reducing the entire inflammatory cascade of the allergic process, especially in chronic forms of allergic conjunctivitis. However, prolonged use is associated to several complications such as increased intraocular pressure and glaucoma, cataracts and more prone to eye infections, including herpetic keratitis(30). Corticosteroids act by binding to cytosolic glucocorticoid receptors (GR). These complexes act at genomic level by decreasing the production of several inflammatory cytokines. The non-genomic effects of this complex and the direct action of glucocorticoids on cell membranes are also described. With these actions there is an inhibition of cell infiltration and fibroblast proliferation, stabilization of intra and extra cellular membranes, blocking of A2 phospholipase and subsequent inhibition of production of membrane metabolites with inflammatory actions, increased production of histaminase and decreased production of histamine. There are several topical presentations of corticosteroids like dexamethasone, fluorometholone, rimexolone, prednisolone and loteprednol(31-32).

Loteprednol etabonate is a new topical steroid with structural modifications where the ketone group at carbon 20 is replaced by an ester group. This modification increases the metabolism and decreases the formation of covalent bonds with proteins of the crystalline, thereby reducing the risk of cataract...
formation and increased intraocular pressure. These aspects are
proved in several studies(31, 32).

Topical corticosteroids are indicated in chronic forms of
unyielded allergic conjunctivitis and acute forms in selected cases(33).

Immunomodulators

The effect of immunomodulators on the eye surface has
been extensively studied in inflammatory diseases as an
alternative to topical corticosteroids due to side effects thereof
and the lack of control in some cases of severe allergic conjunctivitis (AKC, VKC). Cyclosporine and tacrolimus are the
main drugs of this group. The mechanism of action of these drugs
called calcineurin inhibitors occurs via inhibition of the IL-2
receptors present on T lymphocytes and responsible for the
activation(34).

A recently published study demonstrates that the prolonged
use of tacrolimus in the form of 0.1% dermatological ointment is
safe and effective in treating patients with AKC refractory to
conventional treatment, thus demonstrating to be an alternative
in the substitution of topical corticosteroids. In this same study,
the case of a patient with severe AKC is described, which became
blind due to glaucoma acquired by topical corticosteroids and
showed significant improvement of AKC after the use of topical
tacrolimus(35). Comparative studies between ciclosporin 2% and
tacrolimus 0.1% applied topically to severe cases of ocular allergy
show similar effectiveness; however, the burning sensation is more
evident with the use of cyclosporin(36). Cyclosporin in a dose of
0.05% is similar to the placebo in serious ocular allergy
conditions(37), perhaps this being an inadequate concentration to
treat severe forms. Moreover, studies showed good response with
the use of topical tacrolimus 0.03%(38). Regarding the time and
manner of use, studies show that tacrolimus 0.03% and 0.1%
may be applied twice a day at the beginning of the treatment,
and then reduced to a single daily use or even two to three times
a week to maintain the control of symptoms and the inflammatory
process(35-38-39). Despite the favorable findings of the action of
these drugs in controlling allergic inflammation, further studies
are needed to understand the safety profile and the actions and
potential long-term side effects(9-25-32-40-41).

Anti-IgE

Omalizumab is a monoclonal humanized anti-IgE antibody
(IgG1) that binds to free circulating IgE (blood and interstitial
fluid) and B lymphocyte membrane IgE, thus controlling the
inflammatory process mediated hypersensitivity type I. It is
indicated in cases of severe asthma and spontaneous chronic
urticaria in patients older than 12 years(42). The route of
administration is subcutaneous, and it should be performed under
medical supervision in the hospital. Doses may be monthly or
weekly. Reports on the use of omalizumab in severe cases of
AKC and VKC with improvement were published. This is a costly,
not available in many places, not approved medication for
exclusive use in cases of allergic conjunctivitis. Side effects include
headache and rarely anaphylaxis(43).

Specific Immunotherapy: Sublingual and Injection

The specific immunotherapy is a treatment based on the
application of the allergen to which the patient is sensitized at
increasing and continuous doses. There are two main types of
application: oral and subcutaneous. This treatment modality
should be practiced in patients with IgE-mediated disease proven
in vivo or in vitro by skin tests with immediate reading or serum
dosage of specific IgE. It is a long treatment with proven efficacy
which induces immunological tolerance specifically to the
allergen used(44-46). A recent randomized double-blind clinical
study shows the efficacy of sublingual immunotherapy with
Artemisia pollen in patients presenting allergic
rhinoconjunctivitis(47).

PROSPECTS IN THE TREATMENT

Rebamipide

Rebamipide is a gastroprotective drug that increases
gastric mucus secretion and decreases the inflammatory
process(48). In Japan, the presentation in the form of eyedrops 2%
was approved for the treatment of dry eye syndrome.
Rebamipide increases the mucin secretion, and the anti-
inflammatory action on the eye surface occurs by the inhibition
of the activity of tumor necrosis factor alpha on the production
of IL-6 and IL-8 cytokines and the protection of the zonula
occludens with subsequent maintenance of the corneal epithelial
cytokinet. An experimental model of allergic conjunctivitis
was able to reduce the infiltration of eosinophils(49). A recent
study shows a decrease of giant buds significant symptom
improvement with the use of rebamipide 2% eyedrops in patients
with VKC and/or AKC refractory to conventional
pharmacological treatment with symptoms of decreased dry eye
and time of tear film breakup(49). Although further studies are
needed, the use of rebamipide looks promising in the treatment
of eye allergy.

Anti-CCR7

Dendritic cells have been extensively studied as a
therapeutic target in many diseases. They are responsible for
the antigen presentation to T lymphocytes and the secretion of
various cytokines that cause the transformation of T lymphocytes
in different subtypes of lymphocytes (Th1, Th2, Th17, Treg).
Studies have demonstrated the predominance of non-lymphoid
dendritic cells, CD11b+ in the ocular conjunctiva(50). The process
of recognition, antigen processing and presentation of them to
lymphocytes via dendritic cells depends on chemokines and their
respective ligands. CCR7 is a surface protein expressed in
activated dendritic cells and responsible for their traffic to the
peripheral lymphoid organs (where there is the presentation of
antigens) via their ligands CCL19/CCL21 present on the
endothelial surface and lymphatic vessels. Interestingly, after
activation, the dendritic cell itself expresses ligands for CCR7
and the Th0 lymphocytes also express CCR7, favoring the
encounter between the cells for antigen presentation. Thus, the
CCR7 molecule contributes to the antigen-presenting cell traffic,
as well as the persistence of memory Th2 cell activation(51). The
therapeutic opportunity for use of anti-CCR7 on the eye surface
consists in the possibility of blocking the output of dendritic cells
from the eye tissue to the peripheral lymphoid organs. An
experimental model of allergic conjunctivitis in guinea pigs
demonstrates that the use of anti-CCR7 was able to clinically
reduce the signs of allergic conjunctivitis as well as reduce Th2
response and eosinophilic infiltration in the eye surface(52).

CONCLUSION

The ocular allergy conditions, though frequent, are
undiagnosed. Detailed studies on the immunology of the eye

Rev Bras Oftalmol. 2015; 74 (5): 319-24
surface have favored the development of new therapeutic strategies, as well as the rational use of safer and more effective drugs in severe cases. However, it should be noted that the need for further and deeper epidemiological studies, as well as the importance of a multidisciplinary approach to the early diagnosis and the adequate treatment.

References

33. Greiner JV, Edwards-Swanson K, Ingerman A. Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%. Clin Ophthalmol. 2011;5:87-93.

Corresponding author:
Leda das Neves Almeida Sandrin
Rua Barão do Rio Branco, 300-E, Ed. Policlinica Santo Antônio, room 314
Chapecó-SC. Zip Code: 89802-100
E-mail: ledasandrin@clinicasandrin.com.br